The Andhra Pharmaceutical Works Profile
Key Indicators
- Authorised Capital ₹ 0.60 M
as on 22-05-2024
- Paid Up Capital ₹ 0.50 M
as on 22-05-2024
- Company Age 88 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 55.87%
(FY 2017)
- Profit 44.26%
(FY 2017)
- Ebitda 11.44%
(FY 2017)
- Net Worth -61.53%
(FY 2017)
- Total Assets -15.26%
(FY 2017)
About The Andhra Pharmaceutical Works
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.60 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Satyanarayana Alapaty, Baladurgarao Kanigicherla, and Satyanarayana Madupalli serve as directors at the Company.
- CIN/LLPIN
U24239AP1936PLC000091
- Company No.
000091
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Oct 1936
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Krishna, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at The Andhra Pharmaceutical Works?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyanarayana Alapaty  | Managing Director | 18-Sep-1981 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Baladurgarao Kanigicherla | Director | 24-Aug-1991 | Current |
| Satyanarayana Madupalli | Additional Director | 28-Mar-2022 | Current |
Financial Performance of The Andhra Pharmaceutical Works.
The Andhra Pharmaceutical Works Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 55.87% increase. The company also saw a substantial improvement in profitability, with a 44.26% increase in profit. The company's net worth observed a substantial decline by a decrease of 61.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of The Andhra Pharmaceutical Works?
In 2017, The Andhra Pharmaceutical Works had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sri Sai Vissal Enterprises Private LimitedActive 21 years 2 months
Satyanarayana Alapaty is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at The Andhra Pharmaceutical Works?
Unlock and access historical data on people associated with The Andhra Pharmaceutical Works, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of The Andhra Pharmaceutical Works, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped The Andhra Pharmaceutical Works's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
